A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets.
This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world. A firm that advises at the forefront of the forces changing the current of global business and that is unrivalled in its global strength.
Our clients benefit from the collective experience of teams who work with many of the world’s most influential companies and institutions, and have a history of precedent-setting innovations.
Together our lawyers advise more than a third of NYSE-listed businesses, a fifth of the NASDAQ and a notable proportion of the London Stock Exchange, the Euronext, Euronext Paris and the Tokyo and Hong Kong Stock Exchanges.
A&O Shearman advises GSK on a worldwide licensing agreement with HUTCHMED for HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. The deal grants GSK exclusive rights outside of mainland China, Hong Kong, Macau, and Taiwan, with cli
United Kingdom
A&O Shearman has advised global biopharma GSK on its
licensing agreement with HUTCHMED, under which HUTCHMED will
exclusively license to GSK on a worldwide basis (excluding mainland
China, Hong Kong, Macau, and Taiwan) HMPL-A830, a first-in-class
KRAS-EGFR antibody-targeted therapy conjugate (ATTC).
HMPL-A830 is expected to enter clinical trials in H2 2026, with
clinical development initially focusing on colorectal, pancreatic,
and lung cancer indications.
“It was a pleasure to advise GSK on another
significant licensing transaction.”
Jim Ford
Partner
Contributor
A&O Shearman was formed in 2024 via the merger of two historic firms, Allen & Overy and Shearman & Sterling. With nearly 4,000 lawyers globally, we are equally fluent in English law, U.S. law and the laws of the world’s most dynamic markets.
This combination creates a new kind of law firm, one built to achieve unparalleled outcomes for our clients on their most complex, multijurisdictional matters – everywhere in the world. A firm that advises at the forefront of the forces changing the current of global business and that is unrivalled in its global strength.
Our clients benefit from the collective experience of teams who work with many of the world’s most influential companies and institutions, and have a history of precedent-setting innovations.
Together our lawyers advise more than a third of NYSE-listed businesses, a fifth of the NASDAQ and a notable proportion of the London Stock Exchange, the Euronext, Euronext Paris and the Tokyo and Hong Kong Stock Exchanges.
